Business ❯ Pharmaceutical Industry ❯ Drug Development
Novo Nordisk Stock Performance Pricing Strategies Obesity Drug Market GLP-1 Agonists Insurance Coverage Counterfeit Drugs Consumer Behavior Healthcare Funding Eli Lilly
The Dutch buildout underscores a bet on scalable oral GLP-1 supply ahead of an orforglipron obesity filing targeted for late 2025.
